Tilray delivered a record quarter driven by robust international growth, strategic acquisitions, and diversified global platforms, affirming its position as a leading global cannabis and beverage company with over $1 billion in annualized revenue.

• Q3 revenue reached $207 million, marking 11% organic year-over-year growth despite macroeconomic headwinds.
• International cannabis sales surged 73% YoY to $24.1 million, with Germany up 43%, highlighting strong global expansion.
• Medical cannabis sales hit a Q3 high of $83 million, with 35% YoY growth in Tilray Pharma, supported by strategic partnerships in Germany and the UK.
• Gross profit rose 6% to $55 million, maintaining margins amid pricing pressures; cash position remains solid at $265 million.
• Strategic acquisitions like BrewDog position Tilray as a leading global lifestyle and beverage platform, further enhancing long-term growth prospects.